Drug Profile


Alternative Names: Amlodipine/rosuvastatin/fimasartan; BKC-004; Fimasartan/amlodipine/rosuvastatin; Fimasartan/rosuvastatin/amlodipine; Rosuvastatin/amlodipine/fimasartan; Rosuvastatin/fimasartan/amlodipine

Latest Information Update: 20 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipidaemia; Hypertension

Most Recent Events

  • 19 May 2017 Boryung Pharmaceutical plans a phase III trial for Hypertension and Dyslipidaemias (NCT03156842)
  • 01 Aug 2016 Boryung Pharmaceuticals initiates enrolment in a phase I trial in Hypertension (In volunteers) and Hyperlipidemia (In volunteers) in South Korea (NCT02995720)
  • 01 Dec 2015 Boryung Pharmaceuticals completes a phase I trial in Hypertension and Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT02569814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top